Evidence map›Paper›PMID 35468903›Full record

ArticleNPJ Parkinson's disease2022

Lipid level alteration in human and cellular models of alpha synuclein mutations.

Hila Avisar, Cristina Guardia-Laguarta, Matthew Surface, Nikos Papagiannakis, Matina Maniati, Roubina Antonellou, Dimitra Papadimitriou, Christos Koros, Aglaia Athanassiadou, Serge Przedborski and 4 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Hila Avisar *Department of Industrial Engineering & Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Cristina Guardia-Laguarta *Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Matthew SurfaceDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4933-2618
Nikos PapagiannakisFirst Department of Neurology, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID http://orcid.org/0000-0002-8401-8472
Matina ManiatiCenter of Clinical Research, Experimental Surgery and Translational Research, Athens, Greece.
Roubina AntonellouFirst Department of Neurology, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Dimitra PapadimitriouDepartment of Neurology, Henry Dunant Hospital Center, Athens, Greece.
Christos KorosFirst Department of Neurology, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Aglaia AthanassiadouDepartment of Biology, University of Patras Medical School, Athens, Greece.
Serge PrzedborskiDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Boaz LernerDepartment of Industrial Engineering & Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Leonidas StefanisFirst Department of Neurology, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID http://orcid.org/0000-0003-3569-8990
Estela Area-GomezDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Roy N AlcalayDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA. RNA2104@columbia.edu.ORCID http://orcid.org/0000-0002-5717-4875
Columbia University Irving Medical Center · USNational and Kapodistrian University of Athens · GRBen-Gurion University of the Negev · ILHenry Dunant Hospital · GRUniversity of Patras · GR

Funding

Role of C99 in the regulation of lipid metabolism- Relevance to Alzheimer's diseaseR01AG056387 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AREA GOMEZ, ESTELA · 2017 to 2021
$2.1M
The role of glucocerebrosidase in Parkinson's diseaseK02NS080915 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALCALAY, ROY · 2012 to 2016
$905k
NIA NIH HHS R01 AG056387NINDS NIH HHS K02 NS080915Parkinson's Foundation (Parkinson's Foundation, Inc.) Stanley Fahn Junior Faculty AwardU.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) AG056387U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) K02NS080915
6 · The paper itself

Abstract

Lipid profiles in biological fluids from patients with Parkinson's disease (PD) are increasingly investigated in search of biomarkers. However, the lipid profiles in genetic PD remain to be determined, a gap of knowledge of particular interest in PD associated with mutant α-synuclein (SNCA), given the known relationship between this protein and lipids. The objective of this research is to identify serum lipid composition from SNCA A53T mutation carriers and to compare these alterations to those found in cells and transgenic mice carrying the same genetic mutation. We conducted an unbiased lipidomic analysis of 530 lipid species from 34 lipid classes in serum of 30 participants with SNCA mutation with and without PD and 30 healthy controls. The primary analysis was done between 22 PD patients with SNCA+ (SNCA+/PD+) and 30 controls using machine-learning algorithms and traditional statistics. We also analyzed the lipid composition of human clonal-cell lines and tissue from transgenic mice overexpressing the same SNCA mutation. We identified specific lipid classes that best discriminate between SNCA+/PD+ patients and healthy controls and found certain lipid species, mainly from the glycerophosphatidylcholine and triradylglycerol classes, that are most contributory to this discrimination. Most of these alterations were also present in human derived cells and transgenic mice carrying the same mutation. Our combination of lipidomic and machine learning analyses revealed alterations in glycerophosphatidylcholine and triradylglycerol in sera from PD patients as well as cells and tissues expressing mutant α-Syn. Further investigations are needed to establish the pathogenic significance of these α-Syn-associated lipid changes.

Identifiers

PMID35468903
PMCPMC9039073
OpenAlexW4224950545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.